Claudin‐3 – a new intestinal integrity marker in patients with psoriasis: association with disease severity
Background Gut dysbiosis and increased intestinal permeability play a significant role in the pathogenesis of psoriasis and its comorbidities. Claudin‐3 is a key component of tight junctions, which may serve as marker of gut barrier integrity. Objectives The aim of the study was to investigate circu...
Gespeichert in:
| Veröffentlicht in: | Journal of the European Academy of Dermatology and Venereology 2019-10, Vol.33 (10), p.1907-1912 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1912 |
|---|---|
| container_issue | 10 |
| container_start_page | 1907 |
| container_title | Journal of the European Academy of Dermatology and Venereology |
| container_volume | 33 |
| creator | Sikora, M. Chrabąszcz, M. Waśkiel‐Burnat, A. Rakowska, A. Olszewska, M. Rudnicka, L. |
| description | Background
Gut dysbiosis and increased intestinal permeability play a significant role in the pathogenesis of psoriasis and its comorbidities. Claudin‐3 is a key component of tight junctions, which may serve as marker of gut barrier integrity.
Objectives
The aim of the study was to investigate circulating plasma claudin‐3 in patients with psoriasis and to evaluate clinical and metabolic factors, which determine its concentration.
Methods
This cross‐sectional study included 60 patients with psoriasis (39 men and 21 women, mean age: 45.6 ± 12.1 years) and 30 healthy controls (18 men and 12 women, mean age: 46.3 ± 15.5 years) age, sex and body mass index‐matched. Plasma claudin‐3 concentration was measured using an enzyme‐linked immunosorbent assay.
Results
Plasma claudin‐3 concentration was significantly higher in patients with psoriasis in comparison with healthy control [median (interquartile range), 50.7 ng/mL (47.3–54.2) vs. 43.3 ng/mL (42.3–44.2), P |
| doi_str_mv | 10.1111/jdv.15700 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2232121817</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2232121817</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3250-94db0025cc0263357897d7fedeeeea17f3afe41f67e074b9c5ea7ebc0a5a4c9d3</originalsourceid><addsrcrecordid>eNp1kEtOwzAQhi0EgvJYcAHkJSxSxnYSx-xQeQuJDbCNXGcChjQpmZSqO46AxA05CS4BdsxmRjOfPml-xnYFDEWow6fidSgSDbDCBiJOs0hBplbZAIxMI2MSs8E2iZ4AQIgkW2cbSggJKZgBa0aVnRW-_nx7V_zz7YNbXuOc-7pD6nxtq-_xofXdgk9s-4xtWPCp7TzWHfG57x75lJrWW_J0xC1R43y4NnV_KzyhJeSEr7iUbLO10laEOz99i92dnd6OLqLrm_PL0fF15JRMIDJxMQaQiXMgU6USnRld6BILDGWFLpUtMRZlqhF0PDYuQatx7MAmNnamUFtsv_dO2-ZlFn7JJ54cVpWtsZlRLqWSQopM6IAe9KhrG6IWy3za-vDrIheQL_PNQ775d76B3fvRzsYTLP7I30ADcNgDc1_h4n9TfnVy3yu_AGbHiK4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2232121817</pqid></control><display><type>article</type><title>Claudin‐3 – a new intestinal integrity marker in patients with psoriasis: association with disease severity</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Sikora, M. ; Chrabąszcz, M. ; Waśkiel‐Burnat, A. ; Rakowska, A. ; Olszewska, M. ; Rudnicka, L.</creator><creatorcontrib>Sikora, M. ; Chrabąszcz, M. ; Waśkiel‐Burnat, A. ; Rakowska, A. ; Olszewska, M. ; Rudnicka, L.</creatorcontrib><description><![CDATA[Background
Gut dysbiosis and increased intestinal permeability play a significant role in the pathogenesis of psoriasis and its comorbidities. Claudin‐3 is a key component of tight junctions, which may serve as marker of gut barrier integrity.
Objectives
The aim of the study was to investigate circulating plasma claudin‐3 in patients with psoriasis and to evaluate clinical and metabolic factors, which determine its concentration.
Methods
This cross‐sectional study included 60 patients with psoriasis (39 men and 21 women, mean age: 45.6 ± 12.1 years) and 30 healthy controls (18 men and 12 women, mean age: 46.3 ± 15.5 years) age, sex and body mass index‐matched. Plasma claudin‐3 concentration was measured using an enzyme‐linked immunosorbent assay.
Results
Plasma claudin‐3 concentration was significantly higher in patients with psoriasis in comparison with healthy control [median (interquartile range), 50.7 ng/mL (47.3–54.2) vs. 43.3 ng/mL (42.3–44.2), P < 0.001]. Patients who achieved ΔPASI90 response after 16 weeks of treatment showed tendency to decrease in circulating claudin‐3 plasma concentration. Positive correlations between claudin‐3 concentration and the PASI score (r = 0.828; P < 0.001) as well as claudin‐3 and neutrophil‐to‐lymphocyte ratio (r = 0.847; P < 0.001) were found. A multivariable linear regression analysis confirmed association of claudin‐3 with the PASI score (P < 0.001), neutrophil‐to‐lymphocyte ratio (P < 0.01) and active smoking (P < 0.05).
Conclusion
Claudin‐3, a biomarker for gut permeability, is increased in psoriasis and correlates with disease severity and smoking. Further investigations are needed to determine whether reinforcing intestinal barrier may be a new therapeutic target in psoriasis.]]></description><identifier>ISSN: 0926-9959</identifier><identifier>EISSN: 1468-3083</identifier><identifier>DOI: 10.1111/jdv.15700</identifier><identifier>PMID: 31120609</identifier><language>eng</language><publisher>England</publisher><subject>Adult ; Biomarkers - blood ; Claudin-3 - blood ; Cross-Sectional Studies ; Female ; Humans ; Intestinal Mucosa - metabolism ; Lymphocyte Count ; Male ; Middle Aged ; Neutrophils ; Permeability ; Psoriasis - blood ; Severity of Illness Index</subject><ispartof>Journal of the European Academy of Dermatology and Venereology, 2019-10, Vol.33 (10), p.1907-1912</ispartof><rights>2019 European Academy of Dermatology and Venereology</rights><rights>2019 European Academy of Dermatology and Venereology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3250-94db0025cc0263357897d7fedeeeea17f3afe41f67e074b9c5ea7ebc0a5a4c9d3</citedby><cites>FETCH-LOGICAL-c3250-94db0025cc0263357897d7fedeeeea17f3afe41f67e074b9c5ea7ebc0a5a4c9d3</cites><orcidid>0000-0002-6162-9916 ; 0000-0002-8308-1023</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjdv.15700$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjdv.15700$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31120609$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sikora, M.</creatorcontrib><creatorcontrib>Chrabąszcz, M.</creatorcontrib><creatorcontrib>Waśkiel‐Burnat, A.</creatorcontrib><creatorcontrib>Rakowska, A.</creatorcontrib><creatorcontrib>Olszewska, M.</creatorcontrib><creatorcontrib>Rudnicka, L.</creatorcontrib><title>Claudin‐3 – a new intestinal integrity marker in patients with psoriasis: association with disease severity</title><title>Journal of the European Academy of Dermatology and Venereology</title><addtitle>J Eur Acad Dermatol Venereol</addtitle><description><![CDATA[Background
Gut dysbiosis and increased intestinal permeability play a significant role in the pathogenesis of psoriasis and its comorbidities. Claudin‐3 is a key component of tight junctions, which may serve as marker of gut barrier integrity.
Objectives
The aim of the study was to investigate circulating plasma claudin‐3 in patients with psoriasis and to evaluate clinical and metabolic factors, which determine its concentration.
Methods
This cross‐sectional study included 60 patients with psoriasis (39 men and 21 women, mean age: 45.6 ± 12.1 years) and 30 healthy controls (18 men and 12 women, mean age: 46.3 ± 15.5 years) age, sex and body mass index‐matched. Plasma claudin‐3 concentration was measured using an enzyme‐linked immunosorbent assay.
Results
Plasma claudin‐3 concentration was significantly higher in patients with psoriasis in comparison with healthy control [median (interquartile range), 50.7 ng/mL (47.3–54.2) vs. 43.3 ng/mL (42.3–44.2), P < 0.001]. Patients who achieved ΔPASI90 response after 16 weeks of treatment showed tendency to decrease in circulating claudin‐3 plasma concentration. Positive correlations between claudin‐3 concentration and the PASI score (r = 0.828; P < 0.001) as well as claudin‐3 and neutrophil‐to‐lymphocyte ratio (r = 0.847; P < 0.001) were found. A multivariable linear regression analysis confirmed association of claudin‐3 with the PASI score (P < 0.001), neutrophil‐to‐lymphocyte ratio (P < 0.01) and active smoking (P < 0.05).
Conclusion
Claudin‐3, a biomarker for gut permeability, is increased in psoriasis and correlates with disease severity and smoking. Further investigations are needed to determine whether reinforcing intestinal barrier may be a new therapeutic target in psoriasis.]]></description><subject>Adult</subject><subject>Biomarkers - blood</subject><subject>Claudin-3 - blood</subject><subject>Cross-Sectional Studies</subject><subject>Female</subject><subject>Humans</subject><subject>Intestinal Mucosa - metabolism</subject><subject>Lymphocyte Count</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neutrophils</subject><subject>Permeability</subject><subject>Psoriasis - blood</subject><subject>Severity of Illness Index</subject><issn>0926-9959</issn><issn>1468-3083</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kEtOwzAQhi0EgvJYcAHkJSxSxnYSx-xQeQuJDbCNXGcChjQpmZSqO46AxA05CS4BdsxmRjOfPml-xnYFDEWow6fidSgSDbDCBiJOs0hBplbZAIxMI2MSs8E2iZ4AQIgkW2cbSggJKZgBa0aVnRW-_nx7V_zz7YNbXuOc-7pD6nxtq-_xofXdgk9s-4xtWPCp7TzWHfG57x75lJrWW_J0xC1R43y4NnV_KzyhJeSEr7iUbLO10laEOz99i92dnd6OLqLrm_PL0fF15JRMIDJxMQaQiXMgU6USnRld6BILDGWFLpUtMRZlqhF0PDYuQatx7MAmNnamUFtsv_dO2-ZlFn7JJ54cVpWtsZlRLqWSQopM6IAe9KhrG6IWy3za-vDrIheQL_PNQ775d76B3fvRzsYTLP7I30ADcNgDc1_h4n9TfnVy3yu_AGbHiK4</recordid><startdate>201910</startdate><enddate>201910</enddate><creator>Sikora, M.</creator><creator>Chrabąszcz, M.</creator><creator>Waśkiel‐Burnat, A.</creator><creator>Rakowska, A.</creator><creator>Olszewska, M.</creator><creator>Rudnicka, L.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6162-9916</orcidid><orcidid>https://orcid.org/0000-0002-8308-1023</orcidid></search><sort><creationdate>201910</creationdate><title>Claudin‐3 – a new intestinal integrity marker in patients with psoriasis: association with disease severity</title><author>Sikora, M. ; Chrabąszcz, M. ; Waśkiel‐Burnat, A. ; Rakowska, A. ; Olszewska, M. ; Rudnicka, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3250-94db0025cc0263357897d7fedeeeea17f3afe41f67e074b9c5ea7ebc0a5a4c9d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Biomarkers - blood</topic><topic>Claudin-3 - blood</topic><topic>Cross-Sectional Studies</topic><topic>Female</topic><topic>Humans</topic><topic>Intestinal Mucosa - metabolism</topic><topic>Lymphocyte Count</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neutrophils</topic><topic>Permeability</topic><topic>Psoriasis - blood</topic><topic>Severity of Illness Index</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sikora, M.</creatorcontrib><creatorcontrib>Chrabąszcz, M.</creatorcontrib><creatorcontrib>Waśkiel‐Burnat, A.</creatorcontrib><creatorcontrib>Rakowska, A.</creatorcontrib><creatorcontrib>Olszewska, M.</creatorcontrib><creatorcontrib>Rudnicka, L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sikora, M.</au><au>Chrabąszcz, M.</au><au>Waśkiel‐Burnat, A.</au><au>Rakowska, A.</au><au>Olszewska, M.</au><au>Rudnicka, L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Claudin‐3 – a new intestinal integrity marker in patients with psoriasis: association with disease severity</atitle><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle><addtitle>J Eur Acad Dermatol Venereol</addtitle><date>2019-10</date><risdate>2019</risdate><volume>33</volume><issue>10</issue><spage>1907</spage><epage>1912</epage><pages>1907-1912</pages><issn>0926-9959</issn><eissn>1468-3083</eissn><abstract><![CDATA[Background
Gut dysbiosis and increased intestinal permeability play a significant role in the pathogenesis of psoriasis and its comorbidities. Claudin‐3 is a key component of tight junctions, which may serve as marker of gut barrier integrity.
Objectives
The aim of the study was to investigate circulating plasma claudin‐3 in patients with psoriasis and to evaluate clinical and metabolic factors, which determine its concentration.
Methods
This cross‐sectional study included 60 patients with psoriasis (39 men and 21 women, mean age: 45.6 ± 12.1 years) and 30 healthy controls (18 men and 12 women, mean age: 46.3 ± 15.5 years) age, sex and body mass index‐matched. Plasma claudin‐3 concentration was measured using an enzyme‐linked immunosorbent assay.
Results
Plasma claudin‐3 concentration was significantly higher in patients with psoriasis in comparison with healthy control [median (interquartile range), 50.7 ng/mL (47.3–54.2) vs. 43.3 ng/mL (42.3–44.2), P < 0.001]. Patients who achieved ΔPASI90 response after 16 weeks of treatment showed tendency to decrease in circulating claudin‐3 plasma concentration. Positive correlations between claudin‐3 concentration and the PASI score (r = 0.828; P < 0.001) as well as claudin‐3 and neutrophil‐to‐lymphocyte ratio (r = 0.847; P < 0.001) were found. A multivariable linear regression analysis confirmed association of claudin‐3 with the PASI score (P < 0.001), neutrophil‐to‐lymphocyte ratio (P < 0.01) and active smoking (P < 0.05).
Conclusion
Claudin‐3, a biomarker for gut permeability, is increased in psoriasis and correlates with disease severity and smoking. Further investigations are needed to determine whether reinforcing intestinal barrier may be a new therapeutic target in psoriasis.]]></abstract><cop>England</cop><pmid>31120609</pmid><doi>10.1111/jdv.15700</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-6162-9916</orcidid><orcidid>https://orcid.org/0000-0002-8308-1023</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0926-9959 |
| ispartof | Journal of the European Academy of Dermatology and Venereology, 2019-10, Vol.33 (10), p.1907-1912 |
| issn | 0926-9959 1468-3083 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2232121817 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Biomarkers - blood Claudin-3 - blood Cross-Sectional Studies Female Humans Intestinal Mucosa - metabolism Lymphocyte Count Male Middle Aged Neutrophils Permeability Psoriasis - blood Severity of Illness Index |
| title | Claudin‐3 – a new intestinal integrity marker in patients with psoriasis: association with disease severity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T03%3A40%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Claudin%E2%80%903%20%E2%80%93%20a%20new%20intestinal%20integrity%20marker%20in%20patients%20with%20psoriasis:%20association%20with%20disease%20severity&rft.jtitle=Journal%20of%20the%20European%20Academy%20of%20Dermatology%20and%20Venereology&rft.au=Sikora,%20M.&rft.date=2019-10&rft.volume=33&rft.issue=10&rft.spage=1907&rft.epage=1912&rft.pages=1907-1912&rft.issn=0926-9959&rft.eissn=1468-3083&rft_id=info:doi/10.1111/jdv.15700&rft_dat=%3Cproquest_cross%3E2232121817%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2232121817&rft_id=info:pmid/31120609&rfr_iscdi=true |